Relationship between 25-OH-D serum level and relapse rate in multiple sclerosis patients before and after vitamin D supplementation

被引:54
作者
Pierrot-Deseilligny, Charles [1 ]
Rivaud-Pechoux, Sophie [2 ]
Clerson, Pierre
de Paz, Raphael [1 ]
Souberbielle, Jean-Claude [3 ]
机构
[1] Univ Paris 06, Serv Neurol 1, Hop La Pitie Salpetriere, AP HP, Paris, France
[2] Univ Paris 06, INSERM URMS 975, CNRS 7225, Paris, France
[3] Univ Paris 05, Hop Necker Enfants Malad, AP HP, Serv Explorat Fonct, Paris, France
关键词
multiple sclerosis; relapse rate; vitamin D; vitamin D supplementation; ENVIRONMENTAL RISK-FACTORS; PLACEBO-CONTROLLED TRIAL; 25-HYDROXYVITAMIN-D LEVELS; DIAGNOSTIC-CRITERIA; D INSUFFICIENCY; DOUBLE-BLIND; HEALTH; PREVENTION; EFFICACY; THERAPY;
D O I
10.1177/1756285612447090
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Vitamin D could play a protective role in multiple sclerosis. Methods: In an observational, uncontrolled study, vitamin D3 supplementation (3010 IU/day on average) was given to 156 consecutive patients with relapsing-remitting multiple sclerosis, under first-line immunomodulatory therapy and with initial 25-OH-D serum level lower than 100 nmol/l (40 ng/ml). Relapses were determined for 29.1 +/- 8.4 months during vitamin D and 29.8 +/- 10.1 months before supplementation. The 25-OH-D level was measured before supplementation and several times during supplementation. The incidence rate of relapses before and during supplementation was estimated using negative binomial regression models with follow-up durations as offset terms. The incidence rate and incidence rate ratio of relapses at various 25-OH-D levels were also calculated using negative binomial regression models. Results: In 76 patients, immunomodulatory therapy preceded vitamin D supplementation (by 4.2 +/- 2.7 years) and in 80 patients both treatments were started simultaneously. Under supplementation, the 25-OH-D level increased from 49 +/- 22 nmol/l to 110 +/- 26 nmol/l on average. Pooling data collected before and during supplementation, we found a significant strong inverse relationship between the relapse incidence rate and the 25-OH-D level (p < 0.0001), suggesting that vitamin D did indeed influence the relapse rate. Results of univariate, bivariate and multivariate analyses were analogous: in the multivariate model adjusted for age, disease duration and previous use of immunomodulatory therapy, every 10 nmol increase in 25-OH-D level was associated with a reduction in the relapse incidence rate of 13.7%. Dividing iteratively the population made up of pooled periods into two subgroups according to the 25-OH-D levels, the relapse incidence rate ratio decreased as the 25-OH-D level increased up to 110 nmol/l, but a plateau effect was observed beyond this limit. Conclusion: Further studies are warranted for accurate quantification of the vitamin D effect.
引用
收藏
页码:187 / 198
页数:12
相关论文
共 63 条
[1]   Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors [J].
Ascherio, Alberto ;
Munger, Kassandra L. .
ANNALS OF NEUROLOGY, 2007, 61 (06) :504-513
[2]   Vitamin D and multiple sclerosis [J].
Ascherio, Alberto ;
Munger, Kassandra L. ;
Simon, K. Claire .
LANCET NEUROLOGY, 2010, 9 (06) :599-612
[3]   Immunomodulatory effects of vitamin D on monocyte-derived dendritic cells in multiple sclerosis [J].
Bartosik-Psujek, Halina ;
Tabarkiewicz, Jacek ;
Pocinska, Krystyna ;
Stelmasiak, Zbigniew ;
Rolinski, Jacek .
MULTIPLE SCLEROSIS, 2010, 16 (12) :1513-1516
[4]   Evaluation and correction of low vitamin D status [J].
Binkley N. ;
Krueger D. .
Current Osteoporosis Reports, 2008, 6 (3) :95-99
[5]   Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes [J].
Bischoff-Ferrari, Heike A. ;
Giovannucci, Edward ;
Willett, Walter C. ;
Dietrich, Thomas ;
Dawson-Hughes, Bess .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 2006, 84 (01) :18-28
[6]   Prevention of Nonvertebral Fractures With Oral Vitamin D and Dose Dependency A Meta-analysis of Randomized Controlled Trials [J].
Bischoff-Ferrari, Heike A. ;
Willett, Walter C. ;
Wong, John B. ;
Stuck, Andreas E. ;
Staehelin, Hannes B. ;
Orav, John ;
Thoma, Anna ;
Kiel, Douglas P. ;
Henschkowski, Jana .
ARCHIVES OF INTERNAL MEDICINE, 2009, 169 (06) :551-561
[7]   A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis [J].
Burton, J. M. ;
Kimball, S. ;
Vieth, R. ;
Bar-Or, A. ;
Dosch, H. -M. ;
Cheung, R. ;
Gagne, D. ;
D'Souza, C. ;
Ursell, M. ;
O'Connor, P. .
NEUROLOGY, 2010, 74 (23) :1852-1859
[8]   Switching Multiple Sclerosis Patients with Breakthrough Disease to Second-Line Therapy [J].
Castillo-Trivino, Tamara ;
Mowry, Ellen M. ;
Gajofatto, Alberto ;
Chabas, Dorothee ;
Crabtree-Hartman, Elizabeth ;
Cree, Bruce A. ;
Goodin, Douglas S. ;
Green, Ari J. ;
Okuda, Darin T. ;
Pelletier, Daniel ;
Zamvil, Scott S. ;
Vittinghoff, Eric ;
Waubant, Emmanuelle .
PLOS ONE, 2011, 6 (02)
[9]   Measurement uncertainty of 25-OH vitamin D determination with different commercially available kits: impact on the clinical cut offs [J].
Cavalier, E. ;
Rozet, E. ;
Gadisseur, R. ;
Carlisi, A. ;
Monge, M. ;
Chapelle, J. -P. ;
Hubert, P. ;
Souberbielle, J. -C. ;
Delanaye, P. .
OSTEOPOROSIS INTERNATIONAL, 2010, 21 (06) :1047-1051
[10]   Gender Differences in 1,25 Dihydroxyvitamin D3 Immunomodulatory Effects in Multiple Sclerosis Patients and Healthy Subjects [J].
Correale, Jorge ;
Ysrraelit, Maria C. ;
Gaitan, Maria I. .
JOURNAL OF IMMUNOLOGY, 2010, 185 (08) :4948-4958